Elanco Animal Health Incorporated (NYSE: ELAN) today announced its latest entry into the rapidly growing canine dermatology ...

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

Researchers have found in a new real-world study that dupilumab was an effective and safe therapeutic option for head and ...

Maybe your child has been on a specific treatment for atopic dermatitis (also called eczema) for months or even years, but now flare-ups seem to be happening more often and with greater intensity. Or ...

The company said the results of a planned interim analysis met prespecified criteria for early termination of the study. "They did not meet the high-bar efficacy we established for advancing our ...

Elanco Animal Health received approval from the Agriculture Department for Befrena, the company's antibody treatment for canine allergic and atopic dermatitis. The animal-medicine company said ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled ...

Poplar Therapeutics Launches With $50M Series A to Advance a New Class of Anti-IgE Therapy for Multiple Atopic Conditions ...

Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.